For research use only. Not for therapeutic Use.
Carisoprodol is a centrally acting skeletal muscle relaxant of the carbamate class and produces all the effects associated with barbiturate receptor ligands. It is slightly soluble in water and freely soluble in ethanol, chloroform and acetone. The drug/’s solubility is practically independent of pH. Although carisoprodol has significant pharmacological activity, its benefit in therapy is likely due mostly to the meprobamate metabolite as meprobamate remains in the system significantly longer and reaches a higher peak plasma concentration than the parent drug a few hours following administration. This is further evidenced by carisoprodol/’s ability to maintain relevant benefits when administered 3-4 times a day despite its short half-life of only two hours.
| Catalog Number | R009907 |
| CAS Number | 78-44-4 |
| Synonyms | N-(1-Methylethyl)carbamic Acid 2-[[(Aminocarbonyl)oxy]methyl]-2-methylpentyl Ester; Domarax; N-Isopropyl-2-methyl-2-propyl-1,3-propanediol Dicarbamate; Flexal; Isomeprobamate; NIH 10966; NSC 172124; Somalgit; Stialgin; |
| Molecular Formula | C12H24N2O4 |
| Purity | ≥95% |
| Storage | -20°C |
| InChI | InChI=1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16) |
| InChIKey | OFZCIYFFPZCNJE-UHFFFAOYSA-N |
| SMILES | CC(C)NC(OCC(CCC)(C)COC(N)=O)=O |
| Reference | </br>1:Carisoprodol Therapy and <i>CYP2C19</i> Genotype. Dean L.In: Pratt V, McLeod H, Dean L, Malheiro A, Rubinstein W, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-.2017 Apr 4. PMID: 28520382 Free Books & Documents</br>2:Severe Carisoprodol Withdrawal After a 14-Year Addiction and Acute Overdose. Vo KT, Horng H, Smollin CG, Benowitz NL.J Emerg Med. 2017 May;52(5):680-683. doi: 10.1016/j.jemermed.2016.11.015. Epub 2016 Dec 12. PMID: 27979642 </br>3:Impact of Expanding ELISA Screening in DUID Investigations to Include Carisoprodol/Meprobamate and Zolpidem. Lu A, Scott KS, Chan-Hosokawa A, Logan BK.J Anal Toxicol. 2017 Mar 1;41(2):134-139. doi: 10.1093/jat/bkw106. PMID: 27798072 </br>4:Pharmacokinetic modeling of carisoprodol and meprobamate disposition in adults. Lewandowski TA.Hum Exp Toxicol. 2016 Oct 10. pii: 0960327116672912. [Epub ahead of print] PMID: 27758843 </br>5:Mass spectrometric analysis of carisoprodol and meprobamate in rat brain microdialysates. Prokai L, Fryčák P, Nguyen V, Forster MJ.J Mass Spectrom. 2016 Oct;51(10):900-907. doi: 10.1002/jms.3799. PMID: 27747995 </br>6:Carisoprodol withdrawal syndrome resembling neuroleptic malignant syndrome: Diagnostic dilemma. Paul G, Parshotam GL, Garg R.J Anaesthesiol Clin Pharmacol. 2016 Jul-Sep;32(3):387-8. doi: 10.4103/0970-9185.173346. PMID: 27625493 Free PMC Article</br>7:FTIR assay method for UV inactive drug carisoprodol and identification of degradants by RP-HPLC and ESI-MS. Acharya PC, Vasi R, Suares D.J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Sep 1;1029-1030:16-21. doi: 10.1016/j.jchromb.2016.06.041. Epub 2016 Jun 25. PMID: 27398631 </br>8:Quantitation of Carisoprodol and Meprobamate in Urine and Plasma Using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). Slawson MH, Johnson-Davis KL.Methods Mol Biol. 2016;1383:105-14. doi: 10.1007/978-1-4939-3252-8_12. PMID: 26660179 </br>9:Assessment of subunit-dependent direct gating and allosteric modulatory effects of carisoprodol at GABA(A) receptors. Kumar M, González LA, Dillon GH.Neuropharmacology. 2015 Oct;97:414-25. doi: 10.1016/j.neuropharm.2015.04.007. Epub 2015 Apr 18. PMID: 25896767 Free PMC Article</br>10:Factors affecting carisoprodol metabolism in pain patients using urinary excretion data. Tse SA, Atayee RS, Ma JD, Best BM.J Anal Toxicol. 2014 Apr;38(3):122-8. doi: 10.1093/jat/bku002. Epub 2014 Jan 31. PMID: 24488112 |
